Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
February 28, 2023
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
February 15, 2023
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
February 10, 2023
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
January 19, 2023
Palatin Receives $4.7 Million of Non-Dilutive Funding
January 18, 2023
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
January 10, 2023
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
January 5, 2023
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
November 14, 2022
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
November 9, 2022
Palatin Announces $10 Million Registered Direct Offering
October 31, 2022
Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting
October 24, 2022
First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial
October 20, 2022
Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)
October 17, 2022
Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results
October 13, 2022
Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference
September 29, 2022
Palatin to Participate in Ladenburg Thalmann Healthcare Conference
September 29, 2022
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
September 22, 2022
Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022
September 19, 2022
Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis
September 8, 2022
Palatin Announces Intent to Effect Reverse Stock Split
August 19, 2022
Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease
August 16, 2022
Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter
July 26, 2022